NCT06381960招募中2 期
Clinical Study on the Prevention and Treatment of Postoperative Metastasis in Stage IIA-IIIA Lung Cancer With Negative Expression of Driver Genes by Fuzheng Quxie Recipe
Jianhui Tian5 个研究点 分布在 1 个国家目标入组 356 人开始时间: 2023年3月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 356
- 试验地点
- 5
- 主要终点
- Disease-free survival, DFS
研究概览
简要总结
To address the clinical challenge of postoperative metastasis in stage IIA-IIIA non-small cell lung cancer with negative driver gene expression, there is a lack of effective diagnostic and therapeutic measures. Based on this, investigators propose to carry out a clinical study on the prevention and treatment of postoperative metastasis of IIA-IIIA stage lung cancer with negative driver gene expression with the formula of supporting the positive and dispelling the evil.
详细描述
In this study, investigators actively explored the establishment of a combined Chinese and Western medicine prevention and treatment programme in response to the urgent clinical need for the lack of effective diagnostic and therapeutic options for postoperative patients with stage IIA-IIIA non-small cell lung cancer who are clinically negative for the expression of driver genes.
- To objectively evaluate the efficacy of "Fuzheng Quxie Recipe" in preventing and treating postoperative metastasis in stage IIA-IIIA non-small cell lung cancer with negative expression of driver genes, including its effects on disease-free survival, quality of life, and regulation of immune function of the patients, by means of a clinical study in accordance with international standards;
- To test the immunohistology, circulating tumour cells and tiny residual lesions of the patients, and to screen out the population with the advantages of Chinese medicine treatment. Based on this, investigators will establish an efficacy prediction model including the evaluation of peripheral immune function status and the expression level of circulating tumour cells, in order to improve the level of precision treatment after radical lung cancer surgery.
- Through conducting high-level clinical research in line with international standards, obtaining high-level evidence-based medical evidence, screening the advantageous populations of Chinese medicine in treating lung cancer metastasis, and forming a standardised diagnostic and treatment plan/guidelines on Chinese medicine or international guidelines on combining traditional Chinese and Western medicines for the prevention and treatment of post-surgical metastasis of lung cancer that can be promoted and applied, so as to provide a solid scientific basis for the transformation of clinical results and the development of new medicines, and to promote the improvement of the efficiency of the prevention and control of lung cancer as a whole.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with clinical stage IIA-IIIA lung adenocarcinoma after radical surgery (patients within 6 weeks after surgery);
- •Negative driver gene expression (no EGFR, ALK, ROS1 mutations) and PD-1/L1 expression <1%;
- •Meets the diagnostic criteria for Qi-Yin Deficiency Syndrome. The primary symptoms include cough, low sputum, shortness of breath, hoarseness, weakness, and thirst without wanting to drink. Secondary symptoms include spontaneous, night sweat, dysphoria in chestpalms-soles, red tongue or tooth-marked tongue, and a weak pulse. At least two primary symptoms and one of the secondary symptoms are present;
- •Patients aged between 18-75 years;
- •Patients with basically normal blood and biochemical indices, etc., without serious viral or bacterial infections; patients without organ failure and serious heart disease (blood bilirubin <68 μmol/L, aspartate aminotransferase <90 IU/L, creatinine <350 μmol/L, white blood cell count >3.5 × 109/L and less than 12 × 109/L, platelet count >80 × 109/L, and (erythrocyte pressure area >0.20);
- •Tumour PS score ≤2 and no other serious comorbidities;
- •The subjects themselves were well informed and agreed to participate in the study by signing an informed consent form and had good compliance;
- •Non-pregnant and lactating patients;
- •Passing the chemotherapy-related indexes;
- •No allergic reaction to the ingredients in the formula.
排除标准
- •Patients who are incompletely resected or whose cancer has undergone recurrence or metastasis;
- •Patients who are being treated with other drugs or therapies (including other Chinese herbal medicines, immunological drugs, radiotherapy, etc.);
- •Patients who are themselves mentally ill and have a lack of autonomous behaviour;
- •Women who are pregnant, preparing for pregnancy or breastfeeding;
- •Combined heart, lung, brain, liver, kidney and haematopoietic system and other serious diseases, psychiatric patients;
- •Allergic or known hypersensitivity to the components of the drug;
- •Patients who are participating in other clinical trials or have participated in other clinical trials within 3 months;
- •Alcohol and/or psychoactive substances abuse, drug abusers and dependent persons;
- •Other pathologies or conditions that, in the judgement of the investigator, have the effect of reducing the likelihood of enrolment or complicating enrolment, e.g., frequent changes in the work environment, unstable living conditions, and other conditions that predispose to loss of visits.
研究组 & 干预措施
Daily Chinese medicine placebo granules + regular chemotherapy;
Placebo Comparator
Control group
干预措施: Fuzhengquye Fang Recipe simulant (Drug)
Daily Fuzheng Quxie Recipe granules + regular chemotherapy
Experimental
Treatment Group
干预措施: Fuzheng Quxie Recipe (Drug)
结局指标
主要结局
Disease-free survival, DFS
时间窗: Checks were performed before the start of treatment and every 6 months after the procedure. Observational follow-up until 5 years postoperatively.
Refers to the time between the start of randomisation and disease relapse or (for any reason) death. Imaging examination: chest CT examination before the beginning of treatment and every 6 months after the operation. Patients found to have recurrent metastases were discharged from the group for standardised treatment when the pathological diagnosis was clear. Observation and follow-up were carried out until 5 years after the operation, and the calculation of disease-free survival rate, disease-free survival period and median survival period were carried out.
次要结局
- Circulating Tumour Cell Assay(One test was performed before and 6 months after the intervention.)
- Chinese Medicine Symptom Score(Recorded once before and once 6 months after the intervention, continuing for 18 months.)
- Cellular immunity (CD3）(The test was performed once before the intervention and once 6 months after the intervention,continuing for 18 months.)
- Overall survival,OS(The follow-up was observed until 5 years postoperatively, and overall and median survival calculations were performed.)
- Minimal residual disease, MRD(One test was performed before and 6 months after the intervention.)
- Quality of life assessment(Recorded once before and once 6 months after the intervention, continuing for 18 months.)
- Cellular immunity (CD4)(The test was performed once before the intervention and once 6 months after the intervention,continuing for 18 months.)
- Cellular immunity (CD16)(The test was performed once before the intervention and once 6 months after the intervention,continuing for 18 months.)
- regulatory T cells(The test was performed once before the intervention and once 6 months after the intervention,continuing for 18 months.)
- Cellular immunity (CD8)(The test was performed once before the intervention and once 6 months after the intervention,continuing for 18 months.)
- Cellular immunity (CD56）(The test was performed once before the intervention and once 6 months after the intervention,continuing for 18 months.)
- myeloid-derived suppressor cells （MDSCs）(The test was performed once before the intervention and once 6 months after the intervention,continuing for 18 months.)
- CEA(The test was performed once before the intervention and once 6 months after the intervention,continuing for 18 months.)
- SCC(The test was performed once before the intervention and once 6 months after the intervention,continuing for 18 months.)
- Peripheral blood systemic immunoinflammatory index(The test was performed once before the intervention and once 6 months after the intervention, continuing for 18 months.)
- natural killer （NK）cells(The test was performed once before the intervention and once 6 months after the intervention,continuing for 18 months.)
- IL-1(The test was performed once before the intervention and once 6 months after the intervention,continuing for 18 months.)
- IL-2(The test was performed once before the intervention and once 6 months after the intervention,continuing for 18 months.)
- IL-6(The test was performed once before the intervention and once 6 months after the intervention,continuing for 18 months.)
- IL-8(The test was performed once before the intervention and once 6 months after the intervention,continuing for 18 months.)
- IL-10(The test was performed once before the intervention and once 6 months after the intervention,continuing for 18 months.)
- Cyfra21-1(The test was performed once before the intervention and once 6 months after the intervention,continuing for 18 months.)
- CA125(The test was performed once before the intervention and once 6 months after the intervention,continuing for 18 months.)
- CA153(The test was performed once before the intervention and once 6 months after the intervention,continuing for 18 months.)
研究者
Jianhui Tian
professor
Shanghai Municipal Hospital of Traditional Chinese Medicine
研究点 (5)
Loading locations...
相似试验
Unknown
2 期
To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung CancerNon-small Cell Lung Cancer Stage IIIARadiotherapyNCT02977169Shanghai Chest Hospital300
Unknown
2 期
SRS Sequential Sindilimab in Brain Metastasis of NSLSCNSCLC Stage IVBrain MetastasesSintilimabSRSNCT04180501Xiaorong Dong25
已完成
不适用
Postoperative Radiotherapy of Non-small Cell Lung Cancer: Accelerated vs. Conventional FractionationNon-Small Cell Lung CancerNCT02189967Technische Universität Dresden38
招募中
不适用
Interest of Intensive Postoperative Rehabilitation Following Minimally Invasive Lung ResectionLung CancerNCT06202222University Hospital, Rouen184
Unknown
不适用
Lung Cancer Rehabilitation StudyNon Small Cell Lung CancerNCT01258478University Hospital, Geneva390